Editing Biogen (section)

== History ==
Biogen was founded in 1978 in [[Geneva]] as ''Biotechnology Geneva'' by several prominent biologists, including [[Kenneth Murray (biologist)|Kenneth Murray]] from the [[University of Edinburgh]], [[Phillip Allen Sharp]] from the [[Massachusetts Institute of Technology]], [[Walter Gilbert]] from [[Harvard|Harvard University]] (Gilbert served as CEO during the start-up phase of Biogen), Heinz Schaller from the [[University of Heidelberg]], and [[Charles Weissmann]] from the [[University of Zurich]] (Weissmann contributed the first product [[interferon alpha]]).<ref name="NZZ">Werner Grundlehner: [https://www.nzz.ch/wirtschaft/us-behoerde-gibt-gruenes-licht-fuer-zuercher-antikoerper-mit-milliardenpotenzial-ld.1629215 ''Zürcher Antikörper gegen Alzheimer hat Milliardenpotenzial – und Gegenwind.''] Neue Zürcher Zeitung, June 8, 2021. Retrieved June 8, 2021.</ref><ref>{{cite web|title=Biotech's Comeback Kid|url=https://www.forbes.com/sites/matthewherper/2012/12/04/biogen-idec-biotechs-comeback-kid/|access-date=2012-12-04|work=Forbes}}</ref> Gilbert and Sharp were subsequently honored with [[Nobel Prize]]s: Gilbert was recognized in 1980 with the [[Nobel Prize in Chemistry]] for his understanding of [[DNA sequencing]]<ref name=nobelgilbert>{{cite web|url=https://www.nobelprize.org/prizes/chemistry/1980/gilbert/facts/|title=Walter Gilbert|website=[[Nobel Prize]]|access-date=June 3, 2024}}</ref> and Sharp received the [[Nobel Prize in Physiology or Medicine]] in 1993 for his discovery of [[split gene]]s.<ref name=nobelsharp>{{cite web|url=https://www.nobelprize.org/prizes/medicine/1993/sharp/facts/|title=Phillip A. Sharp|website=[[Nobel Prize]]|access-date=June 3, 2024}}</ref>

In 2003, Biogen merged with [[San Diego, California]]-based IDEC Pharmaceuticals (formed in 1985 by [[University of California, San Diego|University of California-San Diego]]'s physicians and immunologists [[Ivor Royston]] and Robert E. Sobol, San Diego bio entrepreneur [[Howard Birndorf]], and Stanford University cancer researchers Ron Levy and Richard Miller) and adopted the name Biogen Idec.<ref>{{Cite web|title=The San Diego Technology Archive|url=https://libraries.ucsd.edu/sdta/companies/idec.html}}</ref><ref name="Exhibit">{{cite web |title=Biogen and IDEC Pharmaceuticals Announce Merger To Create a New Biotechnology Industry Leader |url=https://www.sec.gov/Archives/edgar/data/875045/000104746903021993/a2113458zex-99_1.htm|quote=IDEC — Founded in 1985 to develop monoclonal antibodies. Founders include Ivor Royston, Howard Birndorf, Richard Miller and Brook Byers |website=Exhibit 99.1 |access-date=1 December 2018}}</ref> After the merger, Biogen Idec became the 3rd largest Biotechnology company in the world.<ref>{{cite news|url        = https://www.nytimes.com/2003/06/24/business/idec-to-merge-with-biogen-in-6.8-billion-deal.html|title      = Idec to Merge With Biogen in $6.8 Billion Deal|work  = New York Times |date = 24 June 2003|access-date=2003-06-24|last1 = Pollack|first1 = Andrew}}</ref>

Following shifts in research core areas, the company has since shortened its name, reverting to simply Biogen.<ref>{{cite news|url        = https://www.wsj.com/articles/biogen-drops-idec-from-name-1427113639|title      = Biogen Drops Idec From Name|newspaper  = Wall Street Journal|date = 23 March 2015|access-date=2015-03-23|last1 = Dulaney|first1 = Chelsey}}</ref> Biogen stock is a component of several stock indices such as the [[S&P 500]], [[S&P 1500]], and [[NASDAQ-100]] and the company is listed on the [[NASDAQ]] stock exchange under the ticker symbol, BIIB.<ref>{{cite web|url        = http://www.nasdaq.com/symbol/biib|title      = Biogen Idec Inc. Stock Quote & Summary Data|publisher  = NASDAQ}}</ref>

In May 2006, the company announced it would acquire cancer specialist, Conforma Therapeutics for $250 million.<ref>{{Cite web|date=2006-06-01|title=Biogen Idec agrees to buy Swiss company Fumapharm|url=http://www.pharmatimes.com/news/biogen_idec_agrees_to_buy_swiss_company_fumapharm_996746|access-date=2017-12-28|website=Pharma Times|language=en}}</ref> Later in the same month, the company announced its intention to acquire Fumapharm AG, consolidating ownership of [[Fumaderm]] and [[BG-12]], an oral [[fumarate]], which was being studied for the treatment of [[multiple sclerosis]] and [[psoriasis]].<ref>{{Cite web|title=Biogen Idec to Acquire Fumapharm AG; Consolidates Ownership of Oral Compound BG-12 Being Studied for Multiple Sclerosis|url=http://www.businesswire.com/news/home/20060531005276/en/Biogen-Idec-Acquire-Fumapharm-AG-Consolidates-Ownership|access-date=2017-12-28|website=Businesswire|language=en}}</ref>

In January 2007, the company announced it would acquire Syntonix Pharmaceuticals for up to $120 million, gaining Syntonix's lead product for hemophilia B as well as the technology for developing inhalable treatments.<ref>{{Cite web|title=Biogen to buy Syntonix in $120M deal {{!}} FierceBiotech|url=http://www.fiercebiotech.com/biotech/biogen-to-buy-syntonix-120m-deal|access-date=2017-12-28|website=Fierce Biotech|date=3 January 2007 |language=en}}</ref><ref>{{Cite web|title=Biogen Idec to Acquire Syntonix|url=http://www.businesswire.com/news/home/20070104005533/en/Biogen-Idec-Acquire-Syntonix|access-date=2017-12-28|website=Businesswire|language=en}}</ref>

In 2008, two new brain infection cases from [[Tysabri]] users surfaced in [[Europe]] that raised international concern about Tysabri and its effects with the progressive multifocal [[leukoencephalopathy]] (PML) brain condition. Biogen is one of the drug's producers.<ref>{{Cite web|title=Health Highlights: August 1, 2008|url=https://abcnews.go.com/Health/Healthday/story?id=5499620&page=1|access-date=2021-09-11|website=ABC News|language=en}}</ref>

In 2011, Biogen announced that its drug Fampyra received conditional [[marketing approval]]. Under the conditional approval, Biogen agrees to provide additional data on the long-term benefits and safety of Fampyra.<ref name=":2">{{Cite web|title=TMX Money|url=https://money.tmx.com/fr/quote/BIIB:US/news/5008553463177966|access-date=2021-10-05|website=money.tmx.com}}</ref>

On December 10, 2012, Biogen announced its global collaboration agreement with [[Isis Pharmaceuticals]] to develop and research [[antisense drugs]] to treat [[Neurological disorder|neurological]] and [[neuromuscular disease]]s.<ref>{{Cite web|title=Biogen Idec and Isis Pharmaceuticals Announce Collaboration For Antisense Programs To Treat Neurological Disorders {{!}} Ionis Pharmaceuticals, Inc.|url=https://ir.ionispharma.com/news-releases/news-release-details/biogen-idec-and-isis-pharmaceuticals-announce-collaboration|access-date=2021-10-05|website=ir.ionispharma.com|language=en}}</ref>

In February 2013, [[Bloomberg L.P.|Bloomberg]] broke the news that Biogen was planning to pay [[Élan|Elan]] $3.25 billion for the full rights to [[Tysabri]], used to treat multiple sclerosis.<ref>{{Cite news|date=2013-02-06|title=Biogen to Pay Elan $3.25 Billion for Full Tysabri Rights|work=Bloomberg|url=https://www.bloomberg.com/news/articles/2013-02-06/biogen-to-pay-elan-3-25-billion-for-full-tysabri-rights|access-date=2017-12-28}}</ref>

In 2013, Biogen was the first U.S.-based biotechnology company to appear on the [[Dow Jones Sustainability Indices|Dow Jones Sustainability World Index]].<ref>{{Cite web |date=2021-11-15 |title=Biogen Sets Industry Record with Recognition on Dow Jones Sustainability World Index for 9th Consecutive Year – Company Announcement |url=https://markets.ft.com/data/announce/full?dockey=1330-8393533en-7AVF3T95H006AM8BJAQF09HLDI |access-date=2024-09-09 |website=Financial Times}}</ref>

In January 2015, the company announced that it would acquire Convergence Pharmaceuticals for up to $675 million, with the acquisition aiming to accelerate the development of Convergence's pipeline, in particular [[Raxatrigine|CNV1014802]] – a Phase II small molecule sodium channel blocking candidate.<ref>{{cite web|url=http://www.genengnews.com/gen-news-highlights/biogen-idec-snaps-up-convergence-for-up-to-675m/81250789/|title=Biogen Idec Snaps Up Convergence for Up-to-$675M - GEN News Highlights - GEN|date=12 January 2015 }}</ref> In October 2015, the company announced that it would lay off 11% of its workforce, effective immediately.<ref>{{cite web|url=http://www.businessinsider.com/biogen-layoffs-cutting-11-of-workforce-2015-10|title=Biogen is cutting 11% of its workforce|website=[[Business Insider]] }}</ref>

On May 3, 2016, Biogen announced to spin off its hemophilia business, known as [[Bioverativ]]. The hemophilia business would become an independent publicly traded company. Bioverativ offered two hemophilia drugs in 2016, Alprolix and Eloctate, and plans on developing its Hemophilia-focused goals.<ref>{{Cite web|date=2016-05-03|title=Biogen puzzles Wall Street with plans to spin off its hemophilia business|url=https://www.statnews.com/pharmalot/2016/05/03/biogen-hemophilia-multiple-sclerosis/|access-date=2021-10-05|website=STAT|language=en-US}}</ref>

In 2016, Biogen released Spinraza (nusinersin), a treatment for Spinal Muscular Atrophy. The drug is among the most expensive treatments available, with a price of $750,000 for the first year of doses, and $375,000 for each subsequent year and likely for the rest of a patient's life.<ref>{{Cite news|author=Katie Thomas|url=https://www.nytimes.com/2016/12/30/business/spinraza-price.html|title=Costly Drug for Fatal Muscular Disease Wins F.D.A. Approval|work=The New York Times |date=31 December 2016 |language=en-us|access-date=2022-02-28}}</ref> While there still isn't a cure, Spinraza significantly improves the quality of life in infants and adults.

In 2017, Biogen announced that its drug Fampyra converted from conditional marketing authorization to standard marketing approval. [[European Union|EU]] [[multiple sclerosis]] (MS) patients use Fampyra to improve walking.<ref name=":2" />

In February 2020, Biogen and [[Sangamo Therapeutics]] announced a global licensing deal to develop compounds for neuromuscular and neurological diseases.<ref>{{Cite web|url=https://www.biospace.com/article/biogen-and-sangamo-partner-on-alzheimer-s-parkinson-s-and-others/|title=Biogen and Sangamo Ink $2.7 Billion+ Neurodegeneration Deal|website=BioSpace|date=28 February 2020 |language=en-US|access-date=2020-02-28}}</ref>

In September 2020, Biogen Inc. made a $10 million deposit in [[OneUnited Bank]] to provide more capital to fund home loans and commercial development in Black communities.<ref>{{Cite web|author=Staff Report|title=Biotech company partners with Black-owned bank|url=https://www.miamitimesonline.com/business/biotech-company-partners-with-black-owned-bank/article_04b90e0c-f2b2-11ea-9892-17c9cd391855.html|access-date=2020-09-13|website=The Miami Times|date=9 September 2020 |language=en}}</ref> In November, the company announced it would acquire a $650 million stake in Cambridge-based [[Sage Therapeutics]] and make an upfront payment of $875 million, in order to jointly develop a number of depression treatments.<ref>[https://web.archive.org/web/20201127223831/https://uk.reuters.com/article/us-biogen-sage/biogen-bets-on-depression-drug-in-1-5-billion-deal-with-sage-therapeutics-idUKKBN2871GU Reuters]</ref>

In July 2023, it was announced Biogen had acquired the [[Plano, Texas]]-headquartered biotech company, [[Reata Pharmaceuticals]] for nearly $6.5 billion.<ref>{{Cite news |last1=Mishra |first1=Manas |last2=Satija |first2=Bhanvi |last3=Satija |first3=Bhanvi |date=2023-07-28 |title=Biogen to buy Reata for $6.5 bln to bulk up rare disease portfolio |language=en |work=Reuters |url=https://www.reuters.com/markets/deals/biogen-buy-reata-65-bln-bulk-up-rare-disease-portfolio-2023-07-28/ |access-date=2023-07-28}}</ref>

In May 2024, Biogen acquired Human Immunology Biosciences (HI-Bio) for $1.15 billion.<ref name="auto1">{{Cite web |title=Biogen bulking out mAb pipeline through $1.15bn HI-Bio buy |url=https://www.bioprocessintl.com/deal-making/biogen-bulking-out-mab-pipeline-through-1-15bn-hi-bio-buy |access-date=2024-05-23 |website=www.bioprocessintl.com |language=en}}</ref>

=== Aducanumab ===
{{Main|Aducanumab}}
In 2007, the company reached a licensing agreement with Neurimmune, a spin-off from the University of Zurich, for the [[Alzheimer's disease]] drug, [[Aducanumab]], developed by this [[Switzerland|Swiss]] company. Later, Neurimmune sold its rights for license fees for $200 million to Biogen.<ref name="NZZ" />

In December 2014, Biogen announced that Aducanumab for Alzheimer's treatment was preparing to go through a late-stage trial of its experimental Alzheimer's disease treatment after the medication dramatically improved cognition and reduced brain plaque levels in early-stage study.<ref>{{Cite news|last=Pierson|first=Ransdell|date=2014-12-02|title=Biogen plans late-stage Alzheimer's trial, shares rise|language=en|work=Reuters|url=https://www.reuters.com/article/us-biogen-idec-alzheimers-idINKCN0JG1JX20141202|access-date=2021-09-11}}</ref>

In March 2015, Aducanumab became the first experimental Alzheimer's treatment to show significant results in regard to slowing down cognitive decline and reducing brain-destroying plaques.<ref>{{Cite news|last=Berkrot|first=Bill|date=2015-03-20|title=Biogen's Alzheimer's drug slows mental decline in early study|language=en|work=Reuters|url=https://www.reuters.com/article/us-biogen-alzheimers-idUSKBN0MG1OU20150320|access-date=2021-09-11}}</ref> In July 2015, Biogen initiated two late-stage studies called ENGAGE and EMERGE, which will assess Aducanumab in adults with early Alzheimer's disease.<ref>{{Cite web|date=2015-09-08|title=Biogen Enrolls First Patient in Global Phase 3 Study of Investigational Treatment Aducanumab (BIIB037) for Early Alzheimer's Disease|url=https://www.businesswire.com/news/home/20150908005533/en/Biogen-Enrolls-First-Patient-in-Global-Phase-3-Study-of-Investigational-Treatment-Aducanumab-BIIB037-for-Early-Alzheimer%E2%80%99s-Disease|access-date=2021-09-11|website=www.businesswire.com|language=en}}</ref>

In 2016, Aducanumab decreased amoyloid-beta in the brains of people with early-stage Alzheimer's disease, according to a report published in Nature on August 31, 2016.<ref>{{Cite web|last=Kirsten|title=Investigational antibody treatment yields exciting though preliminary results - UCI MIND|url=https://mind.uci.edu/investigational-antibody-treatment-yields-exciting-though-preliminary-results/|access-date=2021-10-11|language=en-US}}</ref> On March 21, 2019, Biogen announced that the Phase 3 clinical trials of Aducanumab were halted.<ref>{{Cite web|last=Kirsten|title=Phase 3 Trials of Aducanumab Halted - UCI MIND|url=https://www.mind.uci.edu/phase-3-trials-of-aducanumab-halted/|access-date=2021-10-11|language=en-US}}</ref> Biogen announced it would acquire Nightstar Therapeutics for $25.50 per share ($800 million in total). Nightstar focused on adeno-associated virus based gene-therapies for inherited retinal disorders.<ref>{{cite web|title=BIOGEN ANNOUNCES AGREEMENT TO ACQUIRE NIGHTSTAR THERAPEUTICS TO ESTABLISH CLINICAL PIPELINE OF GENE THERAPY CANDIDATES IN OPHTHALMOLOGY|url=https://www.biospace.com/article/biogen-announces-agreement-to-acquire-nightstar-therapeutics-to-establish-clinical-pipeline-of-gene-therapy-candidates-in-ophthalmology/|access-date=2 June 2019|website=BioSpace|date=4 March 2019 }}</ref><ref>{{cite web|title=Biogen Banks on Ophthalmology Gene Therapies With $800 Million Acquisition of Nightstar|url=https://www.biospace.com/article/biogen-banks-on-ophthalmology-gene-therapies-with-800-million-acquisition-of-nightstar/|access-date=2 June 2019|website=BioSpace|date=4 March 2019 }}</ref> With a setback in their drug research, Biogen's shares fell sharply that same month.<ref>{{cite web|last=Annett|first=Timothy|date=21 March 2019|title=Biogen shares plunge after Alzheimer's drug setback|url=https://www.bostonglobe.com/business/2019/03/21/biogen-shares-plunge-after-alzheimer-drug-setback/0MzLJWlEgmo5nHSKWl8esO/story.html|access-date=2 June 2019|work=The Boston Globe}}</ref> It ended the trial of Aducanumab, which it was making along with [[Eisai (company)|Eisai]].<ref>{{cite web|last=Li|first=Yun|date=21 March 2019|title=Biogen posts its the worst day in 14 years after ending trial for blockbuster Alzheimer's drug|url=https://www.cnbc.com/2019/03/21/biogen-shares-plunge-more-than-25percent-after-ending-trial-for-alzheimers-drug-aducanumab.html|access-date=2 June 2019|website=CNBC}}</ref> In October 2019, however, they announced that they would pursue FDA approval together with Eisai.<ref name=":0">{{Cite web|author1=Jacqueline Howard|author2=Jamie Gumbrecht|title=Drugmaker to seek approval for Alzheimer's treatment|url=https://www.cnn.com/2019/10/22/health/biogen-alzheimers-drug-fda/index.html|access-date=2019-10-23|website=CNN|date=22 October 2019 }}</ref>

On October 22, 2019, despite two Phase 3 clinical trials being previously halted for futility, Biogen announced its plan to submit for FDA's approval of Aducanumab.<ref>{{Cite web|last=Chelsea|title=Biogen's About Face - UCI MIND|url=https://www.mind.uci.edu/biogens-about-face/|access-date=2021-10-11|language=en-US}}</ref> In May 2020, Biogen wrapped up construction on a state-of-the-art facility in [[Solothurn]], [[Switzerland]], which will produce Aducanumab by late 2021, alongside its [[North Carolina]] manufacturing facility. The [[monoclonal antibody]], co-developed with [[Eisai (company)|Eisai]], attracted considerable interest from biotech investors when [[Warren Buffett]]'s [[Berkshire Hathaway]] bought 648,447 Biogen shares at a combined value of $192.4 million.<ref>Kyle Blankenship (May 7, 2020). [https://www.fiercepharma.com/manufacturing/biogen-s-swiss-facility-wraps-up-construction-to-help-boost-aducanumab-rollout "Biogen gears up Swiss manufacturing facility for potential aducanumab rollout"] ''Fierce Pharma (Manufacturing)''. Retrieved 9 June 2021.</ref>

On July 8, 2020, Biogen and [[Eisai (company)|Eisai]] announced that both companies had together successfully submitted for Aducanumab's FDA regulatory and marketing approval.<ref>{{Cite web|last=Kirsten|title=Biogen and Eisai submit aducanumab for FDA approval - UCI MIND|url=https://128.200.55.17/biogen-and-eisai-submit-aducanumab-for-fda-approval/|access-date=2021-10-11|language=en-US}}</ref>

On June 7, 2021, the [[FDA]] gave accelerated approval to Aducanumab under the name Aduhelm,<ref>{{Cite web |last=Commissioner |first=Office of the |date=2021-06-07 |title=FDA Grants Accelerated Approval for Alzheimer's Drug |url=https://www.fda.gov/news-events/press-announcements/fda-grants-accelerated-approval-alzheimers-drug |archive-url=https://web.archive.org/web/20210607153129/https://www.fda.gov/news-events/press-announcements/fda-grants-accelerated-approval-alzheimers-drug |url-status=dead |archive-date=June 7, 2021 |access-date=2022-03-22 |website=FDA |language=en}}</ref> which proved to be controversial.<ref>{{Cite news |last1=Belluck |first1=Pam |last2=Kaplan |first2=Sheila |last3=Robbins |first3=Rebecca |date=2021-07-20 |title=How an Unproven Alzheimer's Drug Got Approved |language=en-US |work=The New York Times |url=https://www.nytimes.com/2021/07/19/health/alzheimers-drug-aduhelm-fda.html |access-date=2022-03-22 |issn=0362-4331}}</ref><ref>{{Cite web |last=Lovelace |first=Berkeley Jr. |date=2021-07-09 |title=Biogen stock falls after FDA calls for federal investigation into Alzheimer's drug approval |url=https://www.cnbc.com/2021/07/09/biogen-alzheimers-drug-fda-calls-for-federal-investigation-into-approval.html |access-date=2022-03-22 |website=CNBC |language=en}}</ref> The drug was priced at $56,000 US dollars per year, but it was not covered by many insurers as they awaited further proof that the drug was effective.<ref>{{Cite web |last=King |first=Robert |date=2021-11-22 |title=Major insurers won't pay for Biogen's Alzheimer's drug until they get more proof that it works: Bloomberg survey |url=https://www.fiercehealthcare.com/payer/bloomberg-survey-major-insurers-question-if-controversial-alzheimer-s-drug-medically |access-date=2022-03-22 |website=Fierce Healthcare |language=en}}</ref> The US Government did not subsidise it outside clinical trials.<ref>{{Cite web |last=Liu |first=Angus |date=2022-01-12 |title=For Biogen's Aduhelm, narrow coverage from CMS 'could effectively spell the end': analyst |url=https://www.fiercepharma.com/marketing/biogen-alzheimer-s-drug-aduhelm-cms-restrictive-draft-reimbursement-ruling-could |access-date=2022-03-22 |website=Fierce Pharma |language=en}}</ref> According to the FDA's website, the drug was proven to reduce amyloid-beta plaques in the brain, which was likely to benefit patients. The FDA has stated that if the post-approval trial did not indicate that Aduhelm works, the drug may be taken out of the market.<ref>{{Cite news|last1=Steenhuysen|first1=Julie|last2=Beasley|first2=Deena|date=2021-06-08|title=U.S. approval of Biogen Alzheimer's drug sends shares soaring, hailed as 'big day" for patients|language=en|work=Reuters|url=https://www.reuters.com/business/healthcare-pharmaceuticals/us-fda-set-rule-controversial-biogen-alzheimers-drug-2021-06-07/|access-date=2021-10-11}}</ref>

Biogen abandoned the drug in January 2024, for financial reasons.<ref>{{Cite web |title=Biogen will stop selling its controversial Alzheimer's drug Aduhelm |url=https://abcnews.go.com/Health/wireStory/biogen-plans-shut-controversial-alzheimers-drug-aduhelm-106827709 |access-date=2024-02-01 |website=ABC News |language=en}}</ref>

===Bioverativ===
In May 2016, the company announced that it would [[Corporate spin-off|spin off]] its hemophilia drug business ([[Eloctate]] and [[Alprolix]]) into a public company.<ref>{{cite news | url=https://www.reuters.com/article/us-biogen-hemophilia-idUSKCN0XU15E | title=Biogen to spin off hemophilia drug business into a public company | work=Reuters | date=May 3, 2016 | access-date=May 3, 2016 | author=D'Souza, Savio}}</ref> In August, the company announced that the spun off company would be called [[Bioverativ]], in order to show heritage with Biogen.<ref>{{cite web|url=http://www.fiercepharma.com/pharma/biogen-introduces-spinoff-bioverativ-amid-takeover-buzz|title=Amid takeover chatter, Biogen introduces hemophilia spinoff Bioverativ - FiercePharma|date=10 August 2016 }}</ref> The company would trade on the [[Nasdaq|NASDAQ]] exchange under the ticker symbol BIVV<ref>{{Cite press release|url=http://www.businesswire.com/news/financialpost/20160809005296/en/Biogen-Announces-Bioverativ-Hemophilia-Focused-Company|title=Biogen Announces Bioverativ as Name of New Hemophilia-Focused Company {{!}} Business Wire|website=Businesswire|language=en|access-date=2017-12-28}}</ref><ref>{{cite web|url=https://www.bostonglobe.com/business/2016/08/09/biogen-unveils-name-for-hemophilia-drug-spinoff-bioverativ/2EjLRgOOGpOZJECl3nO4yH/story.html|title=Biogen unveils name for hemophilia drug spinoff: Bioverativ |work=Boston Globe}}</ref> and would look to be spun off in early 2017.<ref>{{cite web|url=http://media.biogen.com/press-release/hemophilia-spin/biogen-announces-bioverativ-name-new-hemophilia-focused-company|title=Biogen Announces Bioverativ as Name of New Hemophilia-Focused Company - Biogen Media|access-date=2016-08-11|archive-url=https://web.archive.org/web/20160813045653/http://media.biogen.com/press-release/hemophilia-spin/biogen-announces-bioverativ-name-new-hemophilia-focused-company|archive-date=2016-08-13|url-status=dead}}</ref> Bioverativ was acquired by [[Sanofi]] in 2018 for about $11.6 billions<ref>{{cite web|url=https://www.globenewswire.com/news-release/2018/01/22/1298161/0/en/Sanofi-to-Acquire-Bioverativ-for-11-6-Billion.html|title=Sanofi to Acquire Bioverativ for $11.6 Billion|date=January 22, 2018|access-date=January 31, 2025|via=Sanofi|archive-url=https://archive.today/20250131210010/https://web.archive.org/web/20180123170819/https://www.globenewswire.com/news-release/2018/01/22/1298161/0/en/Sanofi-to-Acquire-Bioverativ-for-11-6-Billion.html|archive-date=January 31, 2025|url-status=live}}</ref><ref>{{cite web|author=Sudip Kar-Gupta|url=https://www.reuters.com/article/world/sanofi-digs-deep-to-buy-us-haemophilia-group-bioverativ-for-116-billion-idUSKBN1FB08C/|title=Sanofi digs deep to buy U.S. haemophilia group Bioverativ for $11.6 billion|date=January 22, 2018|publisher=[[Reuters]]|access-date=January 31, 2025|archive-url=https://archive.today/20250131210455/https://www.reuters.com/article/world/sanofi-digs-deep-to-buy-us-haemophilia-group-bioverativ-for-116-billion-idUSKBN1FB08C/|archive-date=January 31, 2025|url-status=live}}</ref><ref>{{cite web|url=https://www.france24.com/en/20180122-sanofi-buys-us-haemophilia-treatment-firm-116-bn-0|title=Sanofi buys US haemophilia treatment firm for $11.6 bn|location=Paris|publisher=AFP|access-date=January 31, 2025|date=January 22, 2018|archive-url=https://archive.today/20250131211047/https://web.archive.org/web/20201109014437/https://www.france24.com/en/20180122-sanofi-buys-us-haemophilia-treatment-firm-116-bn-0|archive-date=January 31, 2025|url-status=live}}</ref> ($105 per share in cash).<ref>{{cite web|url=https://www.sec.gov/Archives/edgar/data/1121404/000119312518074806/d538875dex991.htm|title=Sanofi Completes Acquisition of Bioverativ Inc.- Bioverativ Inc. is a fully owned subsidiary of Sanofi|location=Paris|date=March 8, 2018|archive-url=https://archive.today/20250131210315/https://www.sec.gov/Archives/edgar/data/1121404/000119312518074806/d538875dex991.htm|archive-date=January 31, 2025|url-status=live}}</ref>

===Acquisition history===
The following is an illustration of the company's major mergers and acquisitions and historical predecessors (this is not a comprehensive list):
{{Tree list}}
*'''Biogen'''
**Biogen IDEC
***Biogen <small>(Est 1978)</small>
***IDEC Pharmaceuticals
**Conforma Therapeutics <small>(Acq 2006)</small>
**Fumapharm AG <small>(Acq 2006)</small>
**Syntonix Pharmaceuticals <small>(Acq 2007)</small>
**Convergence Pharmaceuticals <small>(Acq 2015)</small>
**Nightstar Therapeutics <small>(Acq 2019)</small>
**[[Reata Pharmaceuticals]] <small>(Acq 2023)</small>
**Human Immunology Biosciences (HI-Bio) <ref name="auto1" />

{{Tree list/end}}

=== COVID-19 pandemic ===
{{See also|COVID-19 pandemic}}
On March 5, 2020, Biogen reported that three individuals who met with their employees at a conference in [[Boston]] had tested positive for [[COVID-19]] the previous week.<ref>{{Cite web|title=3 Who Attended Biogen Meeting in Boston Test Positive for Coronavirus|url=https://www.nbcboston.com/news/local/3-who-attended-biogen-meeting-in-boston-test-positive-for-coronavirus/2086462/|access-date=2020-03-09|website=NBC Boston|date=5 March 2020 |language=en-US}}</ref> On March 6, public health officials reported five new cases associated with the Biogen leadership meeting<ref>{{Cite web|title=Coronavirus Cases Linked to Biogen Boston Meeting: What We Know|url=https://www.nbcboston.com/news/coronavirus/what-we-know-about-the-coronavirus-cases-linked-to-biogens-boston-meeting/2086974/|access-date=2020-03-09|website=NBC Boston|date=6 March 2020 |language=en-US}}</ref><ref>{{Cite web|date=2020-03-06|title=Workers who attended Boston Biogen meeting test positive for coronavirus|url=https://www.wcvb.com/article/workers-who-attended-boston-biogen-meeting-test-positive-for-coronavirus/31252079|access-date=2020-03-09|website=WCVB|language=en}}</ref> and by March 9, Massachusetts health officials had announced 30 new presumptive COVID-19 cases, all connected to the Biogen conference.<ref>{{Cite web|title=Live updates: Multiple Mass. schools closed Monday after 15 new presumptive positive COVID-19 cases reported|url=https://www.boston25news.com/more/blog-latest-coronavirus-cases-news-massachusetts/XZXJA7P3J5ENZFXLRG2YUFWTSI/|access-date=2020-03-09|website=WFXT|language=en-US}}</ref><ref>{{Cite web|date=2020-03-06|title=Top Biogen execs were at meeting where attendees had Covid-19|url=https://www.statnews.com/2020/03/06/biogen-workers-test-positive-for-coronavirus-transmission-linked-to-leadership-meeting/|access-date=2020-03-09|website=STAT|language=en-US}}</ref> Researchers first estimated that the conference would be linked to over 20,000 of the state's [[COVID-19|coronavirus]] cases.<ref>{{Cite web|date=2020-08-25|title=Biogen Conference May Be Tied To 20,000 Massachusetts Coronavirus Cases|url=https://boston.cbslocal.com/2020/08/25/biogen-conference-boston-massachusetts-coronavirus-20000-covid-19/|access-date=2020-08-25|website=CBS Boston|language=en-US}}</ref><ref name=":1" /> Researchers later estimated that up to 300,000 cases worldwide had been caused by the Biogen conference, including 1.6% of all U.S. cases of the coronavirus.<ref name=":1">{{Cite web|title=Genetic 'Fingerprints' Suggest Superspreader Biogen Conference Seeded 40% Of Boston Coronavirus Cases|url=https://www.wbur.org/news/2020/08/25/genetic-fingerprints-biogen-superspreader-boston|access-date=2021-09-27|website=www.wbur.org|date=25 August 2020 |language=en}}</ref>